Dr. Sarah Mitchell
Dr. Sarah Mitchell is a physical therapist specializing in c…
The numbers are devastating: over 16 million people worldwide suffer from opioid use disorder. Over 120,000 annual deaths are attributed to opioids globally. Between 3% and 12% of individuals treated with long-term opioid therapy for chronic pain develop addiction. In 2023, approximately 8.6 million Americans reported active misuse of prescription opioids.
For chronic non-cancer pain, the evidence for long-term opioid benefit is limited, while risks such as tolerance, dependence, overdose, and opioid use disorder require careful monitoring.
The Science of Why Opioids Are Problematic
Opioids bind to mu-opioid receptors in the brain, which not only alters pain perception but also activates the mesolimbic reward system — producing euphoria, sedation, and physical dependence. Two critical concepts explain the addiction trajectory:
Tolerance is a predictable neurobiological adaptation: your body needs progressively higher doses for the same effect. Physical dependence means sudden cessation triggers withdrawal. Both are unavoidable physiological outcomes of chronic daily use and don't constitute addiction by themselves.
Opioid Use Disorder (OUD) is a distinct psychiatric pathology involving compulsive use despite escalating negative consequences. The line between expected adaptation and pathological addiction is critical but often blurred.
The Breakthrough: NaV1.8 Inhibitors
In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid analgesic for moderate to severe acute pain in adults.
How It Works Unlike opioids, suzetrigine selectively inhibits the NaV1.8 voltage-gated sodium channel involved in peripheral pain signaling. By targeting peripheral sensory neurons, it offers a different mechanism for acute pain relief than opioid medications.
Why It Matters Because suzetrigine is not an opioid, it avoids opioid-specific risks such as respiratory depression and opioid-like euphoria. Clinical trials supported its approval for moderate to severe acute pain, but it is still a prescription drug and should be used according to clinician guidance and labeling.
Updated CDC Guidelines
The CDC's 2022 Clinical Practice Guideline includes 12 recommendations and notes that nonopioid therapies are at least as effective as opioids for many common types of acute pain. The guideline advises clinicians to consider steps such as:
- Maximizing nonpharmacologic and nonopioid therapies first
- Using Prescription Drug Monitoring Programs (PDMPs)
- Co-prescribing naloxone for overdose reversal
- Linking patients with OUD to evidence-based treatment
- Never using guidelines to justify abrupt forced tapering
The Safe Alternatives That Work
For Mild to Moderate Pain - **Acetaminophen**: Effective antipyretic and analgesic, but watch for hepatotoxicity - **Topical NSAIDs**: Diclofenac gel delivers localized relief without systemic risks - **Capsaicin cream**: Depletes substance P at the pain site
For Neuropathic Pain - **Gabapentin/Pregabalin**: Suppress neuronal hyperexcitability via calcium channels - **Duloxetine**: Bolsters descending inhibitory pathways via serotonin and norepinephrine
For Inflammatory Pain - **Curcumin**: Some osteoarthritis trials suggest symptom benefits, though supplement quality and interactions matter - **Targeted exercise**: Often recommended as part of chronic pain care, with results varying by condition and adherence
For Severe Acute Pain - **Suzetrigine (Journavx)**: A prescription non-opioid option approved for moderate to severe acute pain in adults - **Nerve blocks**: Targeted injections that halt signal transmission
The Bottom Line
Non-opioid pain care is expanding, but the right option depends on the pain type, medical history, other medications, and treatment goals. Ask your healthcare provider about the full spectrum of non-opioid options available today.